×
About 9,863 results

ALLMedicine™ Cholangiocarcinoma Center

Research & Reviews  3,610 results

Clinical application of indocyanine green fluorescence imaging in laparoscopic lymph no...
https://doi.org/10.1016/j.surg.2021.09.032
Surgery Zhang Y, Zhang Y et. al.

Dec 4th, 2021 - Intrahepatic cholangiocarcinoma is a highly lethal malignancy characterized by lymph node metastasis. This study aimed to evaluate the efficacy of indocyanine green fluorescence for visualization of lymphatic drainage and to assess its clinical ap...

Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time?
https://doi.org/10.1002/hep.32258
Hepatology (Baltimore, Md.); Sapisochin G, Ivanics T et. al.

Dec 4th, 2021 - Cholangiocarcinoma (CCA) represents the second most common primary liver malignancy after hepatocellular carcinoma and has risen in incidence globally in the past decades. Intrahepatic cholangiocarcinoma (iCCA) comprises 20% of all CCAs, with the ...

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell...
https://clinicaltrials.gov/ct2/show/NCT02699606

Dec 3rd, 2021 - This is an open-label (all people know the identity of the intervention), multicenter, phase 2 study to evaluate the clinical efficacy, safety and pharmacokinetics of erdafitinib in Asian participants with advanced NSCLC, urothelial cancer, esopha...

Survival following liver transplantation for locally-advanced, unresectable intrahepati...
https://doi.org/10.1111/ajt.16906
American Journal of Transplantation : Official Journal Of... McMillan RR, Javle M et. al.

Dec 3rd, 2021 - Intrahepatic cholangiocarcinoma (iCCA) has previously been considered a contraindication to liver transplantation (LT). However, recent series showed favorable outcomes for LT after neoadjuvant therapy. Our center developed a protocol for neoadjuv...

Precision N-glycoproteomics reveals elevated LacdiNAc as a novel signature of intrahepa...
https://doi.org/10.1002/1878-0261.13147
Molecular Oncology; Li J, Zhao T et. al.

Dec 3rd, 2021 - Primary liver cancer, mainly comprising hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), remains a major global health problem. Although ICC is clinically different from HCC, their molecular differences are still largely u...

see more →

Guidelines  7 results

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2021.0022
Journal of the National Comprehensive Cancer Network : JN... Benson AB, D'Angelica MI et. al.

May 25th, 2021 - The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcino...

Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd ...
https://doi.org/10.1002/jhbp.870
Journal of Hepato-biliary-pancreatic Sciences; Nagino M, Hirano S et. al.

Dec 2nd, 2020 - The Japanese Society of Hepato-Biliary-Pancreatic Surgery launched the clinical practice guidelines for the management of biliary tract cancers (cholangiocarcinoma, gallbladder cancer, and ampullary cancer) in 2007, then published the 2nd version ...

AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With...
https://doi.org/10.1016/j.cgh.2019.07.011
Clinical Gastroenterology and Hepatology : the Official C... Bowlus CL, Lim JK et. al.

Jul 16th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

Clinical practice guidelines for IgG4-related sclerosing cholangitis.
https://doi.org/10.1002/jhbp.596
Journal of Hepato-biliary-pancreatic Sciences; Kamisawa T, Nakazawa T et. al.

Dec 24th, 2018 - IgG4-related sclerosing cholangitis (IgG4-SC) is a distinct type of cholangitis frequently associated with autoimmune pancreatitis and currently recognized as a biliary manifestation of IgG4-related disease. Although clinical diagnostic criteria o...

Hilar cholangiocarcinoma: expert consensus statement.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527854
HPB : the Official Journal of the International Hepato Pa... Mansour JC, Aloia TA et. al.

Jul 15th, 2015 - An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists met on 15 January 2014 to review current evidence on the management of hilar cholangiocarcinoma in order to establish practice guidelines and...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  134 results

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell...
https://clinicaltrials.gov/ct2/show/NCT02699606

Dec 3rd, 2021 - This is an open-label (all people know the identity of the intervention), multicenter, phase 2 study to evaluate the clinical efficacy, safety and pharmacokinetics of erdafitinib in Asian participants with advanced NSCLC, urothelial cancer, esopha...

National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
https://clinicaltrials.gov/ct2/show/NCT04145141

Dec 3rd, 2021 - Background: Primary liver cancer (PLC) is the 2nd most common cause of cancer-related death worldwide and the one cancer with the fastest rising incidence and mortality in the U.S. PLC consists of two main histological subtypes, i.e., hepatocellul...

Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT04645160

Dec 3rd, 2021 - Background: Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy that remains a clinical challenge with limited treatment options and poor survival. Combination chemotherapy with gemcitabine and cisplatin is the most validated first-...

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
https://clinicaltrials.gov/ct2/show/NCT04238715

Nov 29th, 2021 - The primary purpose of the study is to assess the objective response rate (ORR) of E7090 by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 based on independent imaging review (IIR) in participants with unresectable cholangiocarcinoma wi...

Biliary Drainage Plus HAIC in Locally Advanced pCCA
https://clinicaltrials.gov/ct2/show/NCT05024513

Nov 24th, 2021 - When a patient is not eligible for surgery, chemotherapy with gemcitabine and cisplatin can be considered in advanced biliary tract cancers. However, in the Advanced Biliary Cancer, or ABC-2, trial in patients with pCCA, the efficacy of this regim...

see more →

News  184 results

Dr. Ahn on the Increased Understanding of Cholangiocarcinoma
https://www.onclive.com/view/dr-ahn-on-the-increased-understanding-of-cholangiocarcinoma

Oct 8th, 2021 - Daniel H. Ahn, DO, consultant, Division of Hematology/Oncology, Department of Internal Medicine, assistant professor of medicine, Mayo Clinic, discusses the increased understanding of cholangiocarcinoma. The field’s understanding of cholangioca...

Falchook Sheds Light on Rare Oncogenic Drivers in NSCLC
https://www.onclive.com/view/falchook-sheds-light-on-rare-oncogenic-drivers-in-nsclc

Oct 6th, 2021 - Gerald S. Falchook, MD, MS Patients with mutations in NTRK, RET, MET, HER2, and KRAS G12C have limited therapeutic options, but potentially promising agents are on the horizon, said Gerald S. Falchook, MD, MS, adding that these rare oncogeneic dr...

Nivolumab Followed by TIL Therapy Shows Early Safety, Clinical Activity in Metastatic NSCLC
https://www.onclive.com/view/nivolumab-followed-by-til-therapy-shows-early-safety-clinical-activity-in-metastatic-nsclc

Oct 6th, 2021 - Nivolumab (Opdivo) followed by treatment with tumor-infiltrating lymphocytes (TILs) was generally safe and found to have clinical benefit in patients with metastatic non–small cell lung cancer (NSCLC), according to data from a phase 1 trial (NCT03...

Larotrectinib Update Shows Durable Responses in TRK-positive Cancers
https://www.onclive.com/view/larotrectinib-update-shows-durable-responses-in-trkpositive-cancers

Oct 6th, 2021 - David Hyman, MD Larotrectinib (LOXO-101) induced durable responses in patients with TRK fusion—positive solid tumors, according to updated results for the novel pan-TRK inhibitor published in the New England Journal of Medicine (NEJM).1 Among 55...

Making Headway in GI Malignancies in Miami
https://www.onclive.com/view/making-headway-in-gi-malignancies-in-miami

Oct 6th, 2021 - We recently traveled to Miami, Florida for a State of the Science Summit™ on Gastrointestinal Malignancies. At the meeting, faculty from the Florida Society of Clinical Oncology discussed the novel agents that are generating excitement in advanced...

see more →

Patient Education  8 results see all →